Literature DB >> 18401635

A single center's experience with the Ross procedure in pediatrics.

Edward Kirkpatrick1, Roger Hurwitz, John Brown.   

Abstract

The use of a pulmonary autograft for aortic valve replacement (AVR) has become more prevalent than other forms of AVR in the pediatric population. We reviewed the data on pediatric patients who underwent the Ross procedure at our institution from 1993 to 2005. Sixty patients <18 years old who underwent a Ross procedure had available clinical and echocardiographic data collected and statistical analysis performed. Mortality rate was 3.3%, while overall survival and freedom from reoperation of either the homograft or the autograft were 96.7% and 66.2%, respectively, at 10 years. Freedom from reoperation of the left ventricular outflow tract was 60.5% at 10 years. Echocardiographic data showed aortic regurgitation to be mild or less in 76% of patients by last follow-up, while dilation of the sinuses of Valsalva had occurred in 52%. Compared to other AVR options, the Ross procedure in eligible pediatric patients demonstrates good intermediate survival rates and continued growth potential, yet a time-dependent need for reoperation.

Entities:  

Mesh:

Year:  2008        PMID: 18401635     DOI: 10.1007/s00246-008-9224-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  29 in total

Review 1.  Valve repair and replacement in children.

Authors:  D A Lewis; J S Tweddell
Journal:  Curr Opin Cardiol       Date:  1997-01       Impact factor: 2.161

2.  Ross procedure in infants and toddlers followed into childhood.

Authors:  Ismee A Williams; Jan M Quaegebeur; Daphne T Hsu; Welton M Gersony; Francois Bourlon; Ralph S Mosca; Deborah R Gersony; David E Solowiejczyk
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

Review 3.  Is the Ross procedure as good as we thought it would be?

Authors:  Bradley S Marino; Sara Pasquali; Thomas L Spray; Gil Wernovsky
Journal:  Cardiol Young       Date:  2006-09       Impact factor: 1.093

4.  Fate of the aortic root late after Ross operation.

Authors:  Giovanni Battista Luciani; Gianluca Casali; Alessandro Favaro; Maria Antonia Prioli; Luca Barozzi; Francesco Santini; Alessandro Mazzucco
Journal:  Circulation       Date:  2003-09-09       Impact factor: 29.690

5.  Primary aortic valve replacement with allografts over twenty-five years: valve-related and procedure-related determinants of outcome.

Authors:  O Lund; V Chandrasekaran; R Grocott-Mason; H Elwidaa; R Mazhar; A Khaghani; A Mitchell; C Ilsley; M H Yacoub
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

6.  Mechanical aortic valve replacement: long-term outcomes in children.

Authors:  Ganesh Shanmugam; Kenneth MacArthur; James Pollock
Journal:  J Heart Valve Dis       Date:  2005-03

7.  Intermediate-term results in pediatric aortic valve replacement.

Authors:  F M Lupinetti; B W Duncan; A M Scifres; C T Fearneyhough; K Kilian; G L Rosenthal; F Cecchin; T K Jones; S P Herndon
Journal:  Ann Thorac Surg       Date:  1999-08       Impact factor: 4.330

8.  Pulmonary autograft procedure for aortic valve disease: long-term results of the pioneer series.

Authors:  J C Chambers; J Somerville; S Stone; D N Ross
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

9.  Pulmonary autograft in children: realized growth potential.

Authors:  R C Elkins; C J Knott-Craig; K E Ward; C McCue; M M Lane
Journal:  Ann Thorac Surg       Date:  1994-06       Impact factor: 4.330

10.  Ross operation in children and young adults: the Alder Hey case series.

Authors:  Shahzad Gull Raja; Marco Pozzi
Journal:  BMC Cardiovasc Disord       Date:  2004-04-19       Impact factor: 2.298

View more
  1 in total

1.  Echocardiographic Screening for Postoperative Pericardial Effusion in Children.

Authors:  Gary J Galante; Daryl I Schantz; Kimberley A Myers; Charissa R Pockett; Ivan M Rebeyka; Andrew S Mackie
Journal:  Pediatr Cardiol       Date:  2021-06-04       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.